bioAffinity Technologies, Inc. (BIAF)
- Previous Close
1.9900 - Open
1.9500 - Bid 1.8100 x 100
- Ask 1.9100 x 100
- Day's Range
1.8100 - 1.9800 - 52 Week Range
0.9550 - 3.6200 - Volume
191,127 - Avg. Volume
251,957 - Market Cap (intraday)
21.532M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
www.bioaffinitytech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIAF
Performance Overview: BIAF
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIAF
Valuation Measures
Market Cap
22.91M
Enterprise Value
21.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.87
Price/Book (mrq)
4.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.85%
Return on Equity (ttm)
-99.85%
Revenue (ttm)
2.53M
Net Income Avi to Common (ttm)
-7.94M
Diluted EPS (ttm)
-0.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.82M
Total Debt/Equity (mrq)
32.51%
Levered Free Cash Flow (ttm)
-3.61M
Research Analysis: BIAF
Company Insights: BIAF
BIAF does not have Company Insights